Zacks Research Issues Pessimistic Estimate for GSK Earnings

GSK plc (NYSE:GSK) – Equities researchers at Zacks Research decreased their Q1 2026 earnings per share (EPS) estimates for shares of GSK in a research note issued to investors on Wednesday, December 11th. Zacks Research analyst E. Bagri now anticipates that the pharmaceutical company will earn $1.12 per share for the quarter, down from their prior forecast of $1.14. The consensus estimate for GSK’s current full-year earnings is $4.02 per share. Zacks Research also issued estimates for GSK’s Q2 2026 earnings at $1.12 EPS and Q3 2026 earnings at $1.52 EPS.

Several other equities analysts have also issued reports on GSK. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Thursday. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and decreased their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Down 0.6 %

Shares of GSK stock opened at $33.95 on Monday. The business has a fifty day simple moving average of $36.18 and a 200 day simple moving average of $39.21. The stock has a market cap of $70.36 billion, a PE ratio of 22.05, a price-to-earnings-growth ratio of 1.54 and a beta of 0.64. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. GSK has a 12 month low of $32.83 and a 12 month high of $45.92.

Institutional Investors Weigh In On GSK

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sunbelt Securities Inc. increased its position in shares of GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in GSK by 9.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,542 shares of the pharmaceutical company’s stock valued at $137,000 after purchasing an additional 303 shares in the last quarter. Mesirow Financial Investment Management Inc. increased its position in shares of GSK by 2.0% during the 3rd quarter. Mesirow Financial Investment Management Inc. now owns 16,693 shares of the pharmaceutical company’s stock worth $682,000 after purchasing an additional 323 shares during the last quarter. International Assets Investment Management LLC raised its stake in shares of GSK by 6.3% during the 2nd quarter. International Assets Investment Management LLC now owns 5,535 shares of the pharmaceutical company’s stock worth $213,000 after purchasing an additional 327 shares in the last quarter. Finally, Rehmann Capital Advisory Group boosted its holdings in shares of GSK by 6.3% in the 3rd quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock valued at $232,000 after buying an additional 332 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk acquired 2,791,930 shares of the business’s stock in a transaction dated Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the transaction, the insider now directly owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 19.97 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. 10.00% of the stock is currently owned by company insiders.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be given a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. GSK’s dividend payout ratio is currently 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.